Subgroup analysis indicated that PGM5 expression had significant prognostic value for OS in patients with stage I/II cancer (P = 0.0037) and for RFS in patients with stage I/II cancer (P < 0.0001) and grade G1/G2 cancer (P = 0.0039). The gene discussed is PGM5; the disease is cancer.